Science
Precision Lysin Therapeutics as next-generation antibiotics
Our solution
We are pioneering a new class of targeted biologics called Precision Lysin Therapeutics (PLTs)—engineered to selectively eliminate harmful bacteria. Unlike traditional antibiotics, PLTs are designed for precision: they target specific pathogens while minimizing the risk of antimicrobial resistance. This innovative approach positions PLTs as next-generation antibiotics, offering a transformative solution to life-threatening bacterial infections.
A differentiated mechanism of action
Inspired by antibody-drug conjugates, PLTs are engineered proteins that rapidly and selectively destroy bacterial cell walls—delivering immediate, pathogen-specific killing with a single dose. They function as standalone or combination therapies, effective even against multidrug-resistant Gram-negative infections.
Through a non-replicative, non-metabolic mechanism of action, PLTs minimize resistance development. Scalable via standard recombinant production methods and active under physiological conditions, they represent a new class of antibacterial biologics designed to overcome key limitations of traditional antibiotics.
From design to function
Obulytix's proprietary PLT platform combines synthetic biology, advanced bioinformatics, and automated high-throughput screening to streamline the discovery of novel lysins. By assembling large, diverse recombinant libraries and testing them under physiological conditions, we ensure real-world relevance from the start.
The platform generates rich, multi-dimensional datasets that are analyzed using AI-driven prediction tools, enabling rapid identification of highly effective antibacterial candidates. This integrated approach unlocks new therapeutic possibilities and addresses critical gaps in current lysin development.
From design to function with our
integrated PLT platform
Our proprietary platform combines synthetic biology, advanced bioinformatics, and automated high-throughput screening to streamline the discovery of novel lysins. By assembling large, diverse recombinant libraries and testing them under physiological conditions, we ensure real-world relevance from the start.
The platform generates rich, multi-dimensional datasets that are analyzed using AI-driven prediction tools, enabling rapid identification of highly effective antibacterial candidates. This integrated approach unlocks new therapeutic possibilities and addresses critical gaps in current lysin development.
Lead program
Obulytix’s lead program is advancing a Precision Lysin Therapeutic targeting multidrug-resistant Acinetobacter baumannii—a pathogen frequently associated with hospital-acquired infections in critically ill patients. This high-priority target presents a significant unmet medical need. Currently in preclinical development, our candidates demonstrate rapid and potent bactericidal activity under physiologically relevant conditions. With a novel mechanism of action and strong early data, this program represents a compelling opportunity to address one of the most challenging threats in infectious disease.
